Greetings, and welcome to the American Vanguard Corporation Third Quarter 2012 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Bill Kuser, Director of Investor Relations. Thank you, sir, you may begin.

Well, thank you very much and welcome, everyone, to American Vanguard's third quarter and 9-month earnings review. Our speakers today will be Mr. Eric Wintemute, the Chairman and CEO of American Vanguard; and Mr. David Johnson, the company's Chief Financial Officer. Before beginning, let's take a moment for our usual cautionary reminder. In today’s call, the company may discuss forward-looking information. Such information and statements are based on estimates and assumptions by the company’s management and are subject to various risks and uncertainties that could cause actual results to differ from management’s current expectations. Such factors can include weather conditions, changes in regulatory policy, competitive pressures and various other risks that are detailed in the company’s SEC reports and filings. All forward-looking statements represent the company’s best judgment as of the date of this call, and such information will not necessarily be updated by the company. With that said, we turn it over to Eric.

Thank you, Bill. Good morning, everyone, and welcome. First of all, let me start off by saying that our hearts go out to all of our stakeholders who've been affected by the East Coast storm. Hope that everyone is safe and that recovery from any economic damage is quick and complete. We gather today to report our results for the third quarter and first 9 months of 2012. David and I welcome this opportunity to tell you more about our excellent performance and the prospects that we see on the horizon. I'm going to let David give you more details on the operating and financial metrics. But before I do, I would like to highlight a couple of points. Quarterly revenues were up 23%, gross profit margins were 44%, operating expenses were held to 29% of sales and the all-important bottom line, net income, grew 75% over last year's third quarter. As David will describe, our balance sheet remains very strong with cash and scheduled receivables comfortably covering current liabilities and continuing reduction of long-term debt, and shareholders equity increasing yet again by 5% in the quarter and by 15% during the first 9 months of 2012. So the main themes of our 2012 performance continue to be: solid top line growth, excellent profitability, a very strong balance sheet and an organization focused on sustaining this outstanding record. With that overview, I will now turn the call over to David, who will cover the financial and operating details. I will then return with additional comments about the factors that we see shaping the balance of 2012 and an early view of 2013. David?

Thank you, Eric. As Eric has mentioned, and as you will read on our earnings announcement, sales for the third quarter of 2012 increased by 23% to $91 million, as compared to $74 million in the same quarter of 2011. Within this number, our crop sales were up nearly 25% to $80 million and our non-crop sales were up 10% to $11 million. Our export sales continue to grow strongly and are up 9% quarter-on-quarter. Our crop sales reported here also include a reclassification from operating expense to sales of $4.1 million related to our SmartBox systems, and offset by $4.3 million adjustment to cost of sales. In our 10-Q filing scheduled for tomorrow, you will see a detailed description of sales by product groups. In summary, insecticides recorded sales of approximately 60% over the same quarter of the prior year. This group was driven by very strong demand for Bidrin, Mocap and our group of corn soil insecticides including Aztec, Force and Counter. This is the segment that is impacted by the adjustment related to SmartBox systems that I mentioned a moment ago. Our herbicides, fungicides, fumigants group was down 9% in the quarter on reduced sales of Dacthal herbicide and a slightly lower volume of soil fumigants, relative to the same quarter of the prior year. Lastly, within crop, our other sales were up 37% quarter-over-quarter, largely due to much higher Folex sales. This followed better product availability as a result of the start up of additional manufacturing capacity at our Axis, Alabama facility. Our non-crop sales performed well, ending about 10% above last year at $11 million. The improvement was a net result of improving PCNB sales as we start to see some market share recovery for this efficacious product, offset by strong but comparatively lower sales…

Thank you, David. As the 2012 agricultural season concludes, and we prepare to look forward to the 2013 planting season, let me reflect for a moment on our very successful 2012 accomplishments. Fortunately, this year's drought condition had relatively little effect on our year-to-date performance. Our 2012 corn participation with soil insecticides and Impact herbicide occurred early in the season before the effects of the drought damaged some of the Midwest crop later in the season. More importantly, as a result of reduced corn harvest yield this year, we believe that demand for our products next spring will be strong as growers try to make up for this year's yield setback, with an all-out effort to increase yields in 2013. Our products for cotton held up quite well despite regional drought conditions in the Cotton Belt. Early season pest pressure was significant. We then saw a lull in plant bug infestation during the mid-summer heat, followed by an increased pest pressure late in the season. As a result, our Bidrin foliar cotton insecticide had a very solid year with 9-month sales higher in 2012 than in 2011. And in the autumn, while harvested acres of cotton were down somewhat due to the drought and September weather was not perfect for the use of our Folex harvest defoliant, third quarter Folex sales were quite strong and sales through the 9 months were equivalent to the prior year. As we mentioned the last quarter, we expected our third quarter performance would be driven by shipments of metam soil fumigants and Dibrom sales, our mosquito adulticide. While both of these products did not equal their 2011 third quarter sales, through 9 months, our soil fumigants are running slightly ahead of prior year, while Dibrom sales are slightly behind. Both of these product lines…

[Operator Instructions] Our first question comes from the line of Richard Paget with Imperial Capital.

With herbicides down in the quarter 9%, could you give us a little bit more detail on what the drivers of that were?

We had a little bit of sales of Impact in Q3 last year and we don't -- we currently don't have an inventory. Additionally, I think we're down a little bit with Dacthal, which is our other corn herbicide, so those are the 2 points.

So was that related to the drought or was that just production?

The Dacthal is more timing. I think there was probably a little higher sales of Dacthal in Q2 year-over-year, so it's just timing. Yes, year-over-year, Dacthal was pretty much the same.

Okay. And then going forward with the investments that you've made, do you have the capacity online currently to handle your expected demand going into next year both on the insecticide and the herbicide front?

The herbicide I think we're well covered. On the insecticide, we've increased dramatically our supply. Demand could be stronger than what we have available. But I think we're going to be up significantly.

Okay. So I guess that would be a high-quality problem if that indeed happened. And then, how should we think longer term about the corn soil insecticide cycle in terms of either Monsanto adjusting their GMO seeds or the bugs further developing where you would have to, I guess, tweak your formula to get something to combat them. I mean, is this a 3- to 4-year cycle, something shorter?

From our position, we view this as a time that a cultural practice growth or resurgence, if you will, and we think that this could grow beyond where historic has been. So we definitely see growth going forward. Certainly, genetics will continue to improve, but again, we don't see ourselves being replaced by improvement in genetics. We see that we'll be -- we'll continue to be complementary of yield enhancement improvements.

And our next question comes from the line of Daniel Rizzo with Sidoti & Company. Daniel D. Rizzo - Sidoti & Company, LLC: It seems in the past -- I mean, I know everything's going great with the corn soil insecticide and herbicide. But in the past, there were also some new products in the pipeline like the potato sprout inhibitor. I was wondering if that's still kind of down the road, is it still coming along or is there anything else that you can point to?

Yes. So the potato sprout inhibitor were -- the EPA had requested additional study, which was submitted last month. We've had several discussions with them recently. We're still looking to begin sales in the first quarter 2013. But those conversations with EPA are ongoing now. Daniel D. Rizzo - Sidoti & Company, LLC: Okay. And is there anything else? I mean, is there any other products that you can talk about now or is it -- I mean besides -- I mean things are going really great with what you have, but is there anything else in the pipeline?

Well, we're always in negotiations on new products. We're not announcing anything today, but certainly will as we complete an acquisition deal in the future. Daniel D. Rizzo - Sidoti & Company, LLC: Okay. So great. And then I know inventories were up in anticipation of a strong season in the third quarter. Is that going to be the similar thing in the fourth quarter where there's going to be that more inventory build and then kind of sell out of it into next year or is it going to dwindle down starting in the fourth quarter here?

Yes. We've sold some product, corn soil insecticides. With '13, again, demand is very strong and we're building as fast as we can. Inventories at the end of Q4 may be up. We have certainly strong order expectations for Q4 and Q1, particularly in corn. We expect to see significant growth in those 2 quarters from previous year. Where the inventory is on December 31, I don't know that we have a firm track on it at this point. Daniel D. Rizzo - Sidoti & Company, LLC: Okay. And then are you guys capacity constrained at all? I mean, I know you've done a lot of building out over the last year or so. Do you think you have enough capacity to meet the demand that you expect over the next year?

As I mentioned, I think, on the herbicide, Impact, we're in good shape across our product line with the exception of a couple of the corn soil insecticides. We feel we're in adequate supply position. I think we've mentioned before on Mocap and Nemacur that the supply agreement third-party that keeps us a little constrained on what we can sell there. But again, we've increased our capacity dramatically for our corn soil insecticides and should be able to handle a much larger growing demand.

Our next question comes from the line of Michael Cox with Piper Jaffray.

A few questions on the insecticides. Have you resolved the issue with Syngenta around Force supply and your ability to increase supply from them for your reformulation?

We're not obtaining enough material to meet demand. We do have increase over last year. They have significantly stronger demand, not just here in the United States but also in Europe. And so they're under supply constraints for 2013. Fortunately, again, we've got Aztec, Counter and Smartchoice that can be used to help with that demand increase that we see.

Okay. In terms of the strong demand that you're seeing early in the fall season here, at what point do you need to be thinking about putting customers on allocation?

Well, last year, we laid out a supply plan with each of our customers. We've done that again for the 13th season. And I wouldn't call it an allocation, I think we call it a supply plan. We discuss with each of our key customers what their wishes, expectations are for the year and we've laid out a plan accordingly.

Okay. And if we were to assume that you do sell out of your expanded production, at what point would you need to make a decision about expanding again in 2013? And do you have the potential to do it in a relatively low-cost way like you did this year?

Yes. We've already put that plan in place. So we will have additional capacity for growth for the 2014 season with what I would consider not a significant investment but there'll be some investment.

Sure. Okay. And then my last question is on Mocap and Nemacur, any update on the plan there for sorting out that supply constraint?

We do have plans for increasing our supply position for the 2014 season. They haven't been 100% concluded at this point but we expect to have that pretty well determined over the next 90 days.

Okay. And actually, one last one, if I could. On the corn insecticide, any sign of new entrants into the market as new competition?

No.

Our next question comes from the line of Jay Harris with Goldsmith & Harris. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: Just to understand the footnote on the change in SmartBox accounting, what would the quarterly revenues have been had you not made this change?

If you look at the bottom of the income statement, there's a $4.1 million adjustment to sales. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: And that's just in the third quarter?

Yes. And there was a -- similarly, there was a $4.3 million adjustment to cost of sales. Previously, this has been a fairly small part of our business and we've always reported this as a net expense in operating expenses. But it's beginning to grow and, looking forward, it's looking bigger so it becomes something where recognizing the revenue and cost of sales separately seems to be the most appropriate reporting treatment. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: All right. So the -- and this was made starting July -- this change in accounting was made starting July 1?

This is an adjustment for all of the sales that have occurred this year. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: And it all is in the third quarter?

Yes. It's not a material change this year but, yes. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: So your gross margins on crop chemicals and non-crop chemicals are reduced as a result of this move?

Marginally, yes. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: Okay. With revenues at $90 million and receivables at $104 million, when do those ratios change? [indiscernible] which exceed a quarter of revenues?

Yes. We have -- because of the mix of our sales both domestically and internationally, we've been coming in at around 90, 91, 92 days for quite some time.

Yes. So I guess the question that Jay had, is fourth quarter sales -- at the end of fourth quarter, are we going to have receivables greater than sales? And that certainly is a possibility.

Although we usually see receivables come down a little bit in Q4 because of cash. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: Is this kind of a relationship going to continue into next year?

I anticipate it will.

I think -- but David's got a good point. We don't have programs to try to discount for cash, but there's a lot of cash out there and so that may bring that number down for the end of Q4.

We do have some cash incentives. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: All right. As you think about availability of the active ingredient in Impact for your Impact sales going forward, are you in a position today to comment on whether you think you'll be ordering a greater quantity of Impact for 2014 than you've ordered for 2013?

We have projected that. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: And can you comment on the magnitude of the change?

No. I don't think so at this point. Jay Richard Harris - Goldsmith & Harris Incorporated, Research Division: Okay. All right. Let's see. Just an editorial comment, Eric, the time between the announcement of the conference call and the conference call was a little short this year.

I agree. And I think part of it was -- I think we were definitely delayed a day because of the storm, I think, 2 days? 2 days, yes.

Our next question comes from the line of Bruce Winter, a private investor.

Just 2 quick comments. I think your balance sheet looks terrific and I think Mr. Johnson is doing a great job. And I remember the last time that you had a huge growth spurt, and things are much better this time. And I think you have to look at accrued program costs in conjunction with inventories and receivable. And when you do that, things look very good. You can't look at American Vanguard as a clothing store or something like that.

That's a very astute comment, Bruce. Yes, you're absolutely right.

And then my second comment is, I hope you don't do any more stock splits but if you do, I hope you wait until you do a 2-for-1 split or something like that. Other than that, terrific job.

[Operator Instructions] It appears we have no further questions at this time. I would now like to turn the floor back over to management for closing comments.

Thank you. And thank you, everyone, for participating today and we look forward to updating you at our next conference call. And if we have any significant news in between, we'll certainly let you know. Thank you very much. Bye.

Ladies and gentlemen, this does conclude today's teleconference, you may disconnect your lines at this time. Thank you for your participation and have a wonderful day.